ClinicalTrials.gg
CompletedNCT05558696Updated May 7, 2026Results posted

A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)

A Phase 2 interventional study of Bomedemstat in Polycythemia Vera, sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA). Completed at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 179 studies in Polycythemia Vera with a site in United States — 22 open to participants now, 34 under way, 7 of them phase 3. Polycythemia Vera · United States.

Enrollment
111th of 150
20 · median 40
Started
2023
with 2 others
Phase 2
68 of 179
7 open now
Registered
161st of 179
by date

Among the 179 studies in Polycythemia Vera with a site in United States, this one is the 111th largest by enrollment of the 150 interventional ones that give a count, is one of 3 that started in 2023, is one of 68 in phase 2, and was the 161st registered.

Polycythemia Vera

278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

22 of the 179 studies in Polycythemia Vera with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Polycythemia Vera with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics of the orally administered lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat, in participants with polycythemia vera (PV). At Week 36 of dosing, participants will be assessed for eligibility to receive additional treatment through Week 52. Participants deriving clinical benefit and safely tolerating bomedemstat will qualify for continued treatment at the Investigator's discretion.

Read the detailed description

With Amendment 3, after all ongoing participants have reached 52 weeks of treatment, eligible participants may transition to a bomedemstat extension study if available. With Amendment 4, all secondary PK and participant reported outcome measures were designated as exploratory.

Per protocol, participants who derived clinical benefit (no progressive disease) and safely tolerated drug may have qualified for enrollment into the bomedemstat extension study (NCT06351631).

03

Conditions studied

  • Polycythemia Vera

Browse trials for

Keywords

  • polycythemia vera
  • bomedemstat
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a diagnosis of Polycythemia Vera per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms
  • Has a bone marrow fibrosis score of Grade 0 or Grade 1
  • Has failed at least one standard cytoreductive therapy to lower hematocrit
  • Has a >36 weeks
  • Has discontinued prior cytoreductive therapy for 2 weeks (4 weeks for interferon) prior to study drug initiation

Exclusion criteria

Exclusion Criteria:

  • Has an (ECOG) performance status of 3 or greater
  • Has unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1)
  • Has an uncontrolled active infection
  • Has a known (HIV) infection or active Hepatitis A, or virus infection
  • Has evidence of increased risk of bleeding, including known bleeding disorders
  • Is pregnant or lactating
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Bomedemstat

    Participants will receive bomedemstat daily for 36 weeks and may qualify for additional treatment through Week 52 if deriving clinical benefit.

    Drug: Bomedemstat

Interventions

  • Oral capsule

    Also known as: MK-3543, IMG-7289

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs are reported.

    Time frame: Up to approximately 52 weeks

  2. Number of Participants Who Discontinued Study Intervention Due to AEs

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study intervention due to an AE are reported.

    Time frame: Up to approximately 52 weeks

  3. Percentage of Participants With Sustained 12-week Reduction of Hematocrit (Hct) to <45% Without Concomitant Phlebotomy by Week 36

    Hematocrit (Hct) was analyzed by taking blood samples from participants at designated time points during the study. Participants were considered responders if they achieved a sustained reduction of Hct to \<45% for 12 weeks (84 calendar days) by Week 36 AND there was no concomitant phlebotomy performed during the sustained reduction. Baseline data was defined as the data most recently collected prior to the first dose. A Clopper-Pearson (exact binomial) two-sided 95% confidence interval for the percentage of responders was presented. The percentage of participants who achieved a sustained 12-week reduction of Hct to \<45% without concomitant phlebotomy at Week 36 are reported.

    Time frame: Up to approximately 36 weeks

Secondary outcomes

  1. Duration of Reduction of Hematocrit (Hct) to <45% Without Phlebotomy

    Total response duration was defined as the summation of all Hct \<45% response durations, where an individual response duration starts at the timepoint where the Hct \<45% and ends at the first subsequent occurrence of phlebotomy or Hct \>=45%. Hct was analyzed by taking blood samples from participants at designated time points during the study. Duration of reduction of Hct to \<45% without phlebotomy was presented.

    Time frame: Up to approximately 22 months

  2. Percentage of Participants With Platelet Count ≤ 450 x 10^9/L by Week 36

    Platelet count was analyzed by taking blood samples from participants at designated time points during the study. Participants who enter the study with platelet counts ≤450 X 10\^9/L must achieve an additional on-study platelet count ≤450 X 10\^9/L to be considered responders. A Clopper-Pearson (exact binomial) two-sided 95% confidence interval for the percentage of responders is presented. Baseline data was defined as the data most recently collected prior to the first dose. The percentage of participants who have a platelet count ≤450 X 10\^9/L by week 36 are reported.

    Time frame: Up to approximately 36 weeks

  3. Duration of Platelet Count ≤ 450 x 10^9/L

    Total response duration was defined as the summation of all platelet ≤450 x 10\^9/L response durations, where an individual response duration starts at the timepoint where platelet count ≤450 x 10\^9/L and ends at the first subsequent occurrence of platelet \>450 x 10\^9/L. Platelet counts were analyzed by taking blood samples from participants at designated time points during the study. The duration of platelet count ≤450 X 10\^9/L in participants are reported.

    Time frame: Up to approximately 22 months

  4. Percentage of Participants With White Blood Cell (WBC) Count <10 x 10^9/L by Week 36

    WBC count was analyzed by taking blood samples from participants at designated time points during the study. Participants who enter the study with WBC counts \<10 X 10\^9/L must achieve an additional on-study WBC count \<10 X 10\^9/L to be considered responders. A Clopper-Pearson (exact binomial) two-sided 95% confidence interval for the percentage of responders is presented. Baseline data was defined as the data most recently collected prior to the first dose. The percentage of participants who have a WBC count \<10 X 10\^9/L week 36 are reported.

    Time frame: Up to approximately 36 weeks

  5. Duration of White Blood Cell (WBC) Count <10 x 10^9/L

    Total response duration was defined as the summation of all WBC \<10 x 10\^9/L response durations, where an individual response duration starts at the timepoint when WBC \<10 x 10\^9/L and ends at the first subsequent occurrence of WBC ≥ 10 x 10\^9/L. WBC count was analyzed by taking blood samples from participants at designated time points during the study. The duration of WBC count \<10 X 10\^9/L in participants are reported.

    Time frame: Up to approximately 22 months

  6. Number of Participants With Thrombotic Events

    Thrombotic events are defined as: new or recurrent acute myocardial infarction; unstable angina; stroke; transient ischemic attack (TIA); deep venous thrombosis (DVT); pulmonary embolism (PE); thrombotic digital ischemia; other thrombotic events such as peripheral limb ischemia or Budd-Chiari syndrome that are assessed to be due to underlying polycythemia vera (PV); other vascular occlusive events such as symptoms of cardiac, abdominal or peripheral limb ischemia supported by objective evidence of vessel disease and/or ischemia. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with thrombotic events are reported.

    Time frame: Up to approximately 22 months

  7. Number of Participants With Major Hemorrhagic Events

    Hemorrhagic events were defined as: Major Bleeding (MB) Events such as fatal bleeding, and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells; Clinically Relevant Non-Major Bleeding (CRNMB) Events Leading to hospitalization or increased level of care or clinically important, prompting a face-to-face medical evaluation. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with major hemorrhagic events are reported.

    Time frame: Up to approximately 22 months

  8. Number of Participants With an Enlarged Spleen at Baseline Who Had a Reduction in Splenic Volume by 36 Weeks

    Spleen volume was measured by magnetic resonance imaging (MRI) (or computerized tomography \[CT\] if participant is not a candidate for MRI) of the abdomen according to standard procedures. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with an enlarged spleen at baseline (volume \>450 cm\^3) who achieved any reduction in spleen volume by Week 36 are reported.

    Time frame: Up to approximately 36 weeks

  9. Number of Participants With Progressive Disease (PD)

    PD was defined as the worsening of Polycythemia Vera (PV) to post-PV myelofibrosis, myelodysplastic syndrome or transformation to acute myeloid leukemia. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with PD are reported.

    Time frame: Up to approximately 52 weeks

07

Results

Posted May 7, 2026

Participant flow

This study recruited participants with Polycythemia Vera (PV) requiring cytoreduction that have failed at least one standard cytoreductive therapy (failure is the equivalent of resistance or intolerance).

Participant flow — Overall Study
MilestoneBomedemstat
Started20
Completed5
Not completed15
Withdrew: Withdrawal by subject4
Withdrew: Progressive disease1
Withdrew: Physician decision2
Withdrew: Death1
Withdrew: Transition into extension study7

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs are reported.

Time frame:
Up to approximately 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsBomedemstat
Number of Participants With Adverse Events (AEs)20
PrimaryNumber of Participants Who Discontinued Study Intervention Due to AEs

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study intervention due to an AE are reported.

Time frame:
Up to approximately 52 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Intervention Due to AEs
ParticipantsBomedemstat
Number of Participants Who Discontinued Study Intervention Due to AEs0
PrimaryPercentage of Participants With Sustained 12-week Reduction of Hematocrit (Hct) to <45% Without Concomitant Phlebotomy by Week 36

Hematocrit (Hct) was analyzed by taking blood samples from participants at designated time points during the study. Participants were considered responders if they achieved a sustained reduction of Hct to \<45% for 12 weeks (84 calendar days) by Week 36 AND there was no concomitant phlebotomy performed during the sustained reduction. Baseline data was defined as the data most recently collected prior to the first dose. A Clopper-Pearson (exact binomial) two-sided 95% confidence interval for the percentage of responders was presented. The percentage of participants who achieved a sustained 12-week reduction of Hct to \<45% without concomitant phlebotomy at Week 36 are reported.

Time frame:
Up to approximately 36 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained 12-week Reduction of Hematocrit (Hct) to <45% Without Concomitant Phlebotomy by Week 36
Percentage of ParticipantsBomedemstat
Percentage of Participants With Sustained 12-week Reduction of Hematocrit (Hct) to <45% Without Concomitant Phlebotomy by Week 3645.0 (23.1 to 68.5)
SecondaryDuration of Reduction of Hematocrit (Hct) to <45% Without Phlebotomy

Total response duration was defined as the summation of all Hct \<45% response durations, where an individual response duration starts at the timepoint where the Hct \<45% and ends at the first subsequent occurrence of phlebotomy or Hct \>=45%. Hct was analyzed by taking blood samples from participants at designated time points during the study. Duration of reduction of Hct to \<45% without phlebotomy was presented.

Time frame:
Up to approximately 22 months
Reported as:
Median · Months
Duration of Reduction of Hematocrit (Hct) to <45% Without Phlebotomy
MonthsBomedemstat
Duration of Reduction of Hematocrit (Hct) to <45% Without Phlebotomy6.4 (0.3 to 21.2)
SecondaryPercentage of Participants With Platelet Count ≤ 450 x 10^9/L by Week 36

Platelet count was analyzed by taking blood samples from participants at designated time points during the study. Participants who enter the study with platelet counts ≤450 X 10\^9/L must achieve an additional on-study platelet count ≤450 X 10\^9/L to be considered responders. A Clopper-Pearson (exact binomial) two-sided 95% confidence interval for the percentage of responders is presented. Baseline data was defined as the data most recently collected prior to the first dose. The percentage of participants who have a platelet count ≤450 X 10\^9/L by week 36 are reported.

Time frame:
Up to approximately 36 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Platelet Count ≤ 450 x 10^9/L by Week 36
Percentage of ParticipantsBomedemstat
Percentage of Participants With Platelet Count ≤ 450 x 10^9/L by Week 3690.0 (68.3 to 98.8)
SecondaryDuration of Platelet Count ≤ 450 x 10^9/L

Total response duration was defined as the summation of all platelet ≤450 x 10\^9/L response durations, where an individual response duration starts at the timepoint where platelet count ≤450 x 10\^9/L and ends at the first subsequent occurrence of platelet \>450 x 10\^9/L. Platelet counts were analyzed by taking blood samples from participants at designated time points during the study. The duration of platelet count ≤450 X 10\^9/L in participants are reported.

Time frame:
Up to approximately 22 months
Reported as:
Median · Months
Duration of Platelet Count ≤ 450 x 10^9/L
MonthsBomedemstat
Duration of Platelet Count ≤ 450 x 10^9/L11.3 (0.0 to 18.1)
SecondaryPercentage of Participants With White Blood Cell (WBC) Count <10 x 10^9/L by Week 36

WBC count was analyzed by taking blood samples from participants at designated time points during the study. Participants who enter the study with WBC counts \<10 X 10\^9/L must achieve an additional on-study WBC count \<10 X 10\^9/L to be considered responders. A Clopper-Pearson (exact binomial) two-sided 95% confidence interval for the percentage of responders is presented. Baseline data was defined as the data most recently collected prior to the first dose. The percentage of participants who have a WBC count \<10 X 10\^9/L week 36 are reported.

Time frame:
Up to approximately 36 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With White Blood Cell (WBC) Count <10 x 10^9/L by Week 36
Percentage of ParticipantsBomedemstat
Percentage of Participants With White Blood Cell (WBC) Count <10 x 10^9/L by Week 3675.0 (50.9 to 91.3)
SecondaryDuration of White Blood Cell (WBC) Count <10 x 10^9/L

Total response duration was defined as the summation of all WBC \<10 x 10\^9/L response durations, where an individual response duration starts at the timepoint when WBC \<10 x 10\^9/L and ends at the first subsequent occurrence of WBC ≥ 10 x 10\^9/L. WBC count was analyzed by taking blood samples from participants at designated time points during the study. The duration of WBC count \<10 X 10\^9/L in participants are reported.

Time frame:
Up to approximately 22 months
Reported as:
Median · Months
Duration of White Blood Cell (WBC) Count <10 x 10^9/L
MonthsBomedemstat
Duration of White Blood Cell (WBC) Count <10 x 10^9/L6.5 (0.0 to 18.2)
SecondaryNumber of Participants With Thrombotic Events

Thrombotic events are defined as: new or recurrent acute myocardial infarction; unstable angina; stroke; transient ischemic attack (TIA); deep venous thrombosis (DVT); pulmonary embolism (PE); thrombotic digital ischemia; other thrombotic events such as peripheral limb ischemia or Budd-Chiari syndrome that are assessed to be due to underlying polycythemia vera (PV); other vascular occlusive events such as symptoms of cardiac, abdominal or peripheral limb ischemia supported by objective evidence of vessel disease and/or ischemia. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with thrombotic events are reported.

Time frame:
Up to approximately 22 months
Reported as:
Count of participants · Participants
Number of Participants With Thrombotic Events
ParticipantsBomedemstat
Number of Participants With Thrombotic Events0
SecondaryNumber of Participants With Major Hemorrhagic Events

Hemorrhagic events were defined as: Major Bleeding (MB) Events such as fatal bleeding, and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells; Clinically Relevant Non-Major Bleeding (CRNMB) Events Leading to hospitalization or increased level of care or clinically important, prompting a face-to-face medical evaluation. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with major hemorrhagic events are reported.

Time frame:
Up to approximately 22 months
Reported as:
Count of participants · Participants
Number of Participants With Major Hemorrhagic Events
ParticipantsBomedemstat
Number of Participants With Major Hemorrhagic Events1
SecondaryNumber of Participants With an Enlarged Spleen at Baseline Who Had a Reduction in Splenic Volume by 36 Weeks

Spleen volume was measured by magnetic resonance imaging (MRI) (or computerized tomography \[CT\] if participant is not a candidate for MRI) of the abdomen according to standard procedures. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with an enlarged spleen at baseline (volume \>450 cm\^3) who achieved any reduction in spleen volume by Week 36 are reported.

Time frame:
Up to approximately 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With an Enlarged Spleen at Baseline Who Had a Reduction in Splenic Volume by 36 Weeks
ParticipantsBomedemstat
Number of Participants With an Enlarged Spleen at Baseline Who Had a Reduction in Splenic Volume by 36 Weeks6
SecondaryNumber of Participants With Progressive Disease (PD)

PD was defined as the worsening of Polycythemia Vera (PV) to post-PV myelofibrosis, myelodysplastic syndrome or transformation to acute myeloid leukemia. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with PD are reported.

Time frame:
Up to approximately 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Progressive Disease (PD)
ParticipantsBomedemstat
Number of Participants With Progressive Disease (PD)1

Adverse events

Collected over Up to approximately 22 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bomedemstat1/20 (5%)8/20 (40%)20/20 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventBomedemstat
AnaemiaBlood and lymphatic system disorders1/20
Cardiac failureCardiac disorders1/20
VertigoEar and labyrinth disorders1/20
DiverticulitisInfections and infestations1/20
Osteomyelitis acuteInfections and infestations1/20
Wound infectionInfections and infestations1/20
HyperkalaemiaMetabolism and nutrition disorders1/20
EncephalopathyNervous system disorders1/20
Haemorrhagic strokeNervous system disorders1/20
HeadacheNervous system disorders1/20
Most frequent other events
Showing 10 of 40
Most frequent other events
EventBomedemstat
ConstipationGastrointestinal disorders9/20
DiarrhoeaGastrointestinal disorders8/20
FatigueGeneral disorders8/20
DysgeusiaNervous system disorders8/20
NauseaGastrointestinal disorders7/20
ArthralgiaMusculoskeletal and connective tissue disorders7/20
ContusionInjury, poisoning and procedural complications6/20
PruritusSkin and subcutaneous tissue disorders6/20
Abdominal painGastrointestinal disorders5/20
HeadacheNervous system disorders5/20

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Bomedemstat
Mean65.0 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Bomedemstat
Female5
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bomedemstat
Hispanic or Latino0
Not Hispanic or Latino20
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bomedemstat
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White20
More than one race0
Unknown or Not Reported0
Mean Hematocrit Counts at Baseline
Mean Hematocrit Counts at Baseline(Percentage)Bomedemstat
Mean43.99 ± 4.27
08

Study locations

17 sites
  • BRCR Global ( Site 0120)
    Plantation, Florida 33322, United States
  • Hematology Oncology of the North Shore ( Site 0104)
    Skokie, Illinois 60076-1264, United States
  • University of Michigan Comprehensive Cancer Center ( Site 0008)
    Ann Arbor, Michigan 48109, United States
  • Comprehensive Cancer Centers of Nevada - Peak ( Site 0118)
    Las Vegas, Nevada 89128, United States
  • Duke University Medical Center ( Site 0016)
    Durham, North Carolina 27705, United States
  • Ohio State University Comprehensive Cancer Center ( Site 0103)
    Columbus, Ohio 43203, United States
  • OHSU Knight Cardiovascular Institute Cardiology Clinic - South Waterfront ( Site 0102)
    Portland, Oregon 97239-4503, United States
  • Huntsman Cancer Hospital at the University of Utah ( Site 0119)
    Salt Lake City, Utah 84112, United States
  • Sunshine Coast Hematology and Oncology Clinic (Site 0506)
    Sunshine Coast, Queensland 4556, Australia
  • Monash Medical Centre ( Site 0006)
    Clayton, Victoria 3168, Australia
  • Royal Perth Hospital ( Site 0504)
    Perth, Western Australia 6000, Australia
  • Gloucestershire Royal Hospital ( Site 0205)
    Gloucester, England GL1 3NN, United Kingdom
  • United Lincolnshire Hospitals NHS Trust ( Site 0204)
    Lincoln, Great Britain LN2 5QY, United Kingdom
  • Imperial College London ( Site 0025)
    London, Great Britain W12 0HS, United Kingdom
  • Boston Pilgrim Hospital ( Site 0207)
    Boston, Lincolnshire PE21 9QS, United Kingdom
  • Guys and St Thomas NHS Foundation Trust - Guys Hospital ( Site 0020)
    London, London, City of SE1 9RT, United Kingdom
  • Royal Gwent Hospital ( Site 0201)
    Newport, Wales NP9 2UB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Mar 2025, 18 months.

Results were first posted in May 2026, 1 year 1 month after primary completion.

Of 44 phase 2 interventional studies under Polycythemia Vera, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 135. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2022
First posted
Sep 28, 2022
StartActual
Sep 7, 2023
Primary completionActual
Mar 24, 2025
CompletionActual
Jul 10, 2025
Results first posted
May 7, 2026
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05558696
Responsible party
Sponsor
First posted
Sep 28, 2022
Start date
Sep 7, 2023
Primary completion
Mar 24, 2025
Completion
Jul 10, 2025
Results posted
May 7, 2026
Last update
May 7, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bomedemstat

Start the discussion